About human papillomav irus l
Recombinant human papillomavirus vaccine
Used for
- Prevents cancers and precancers caused by HPV types included in the vaccine
- Prevents genital warts caused by HPV types 6 and 11
Usual adult dose
0.5 mL injected into muscle. Two doses, six to twelve months apart, if vaccination starts before age 15; otherwise three doses at 0, 1–2, and 6 months.
Usual dose in children
0.5 mL injected into muscle. Start at ages 9–14: two doses, six to twelve months apart. Start at age 15 or older: three doses at 0, 1–2, and 6 months.
Common side effects
- Pain, redness, or swelling at the injection site
- Headache
- Fever
- Dizziness or fainting
Important warnings
- Not for treatment of existing HPV infection or related disease
- Delay vaccination during moderate or severe acute illness
- Fainting can occur; observe recipients for 15 minutes after vaccination
- Avoid in people with severe allergic reaction to a prior dose or vaccine component
Pregnancy
Vaccination is not recommended during pregnancy; remaining doses can be given after pregnancy. Available data have not identified a pregnancy-related safety concern.
Breastfeeding
Can be given while breastfeeding.
Interactions
- May be given with other vaccines at separate injection sites
- Medicines that suppress the immune system may reduce the immune response
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.